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Abstract
Background: Schizophrenia is a common psychiatric disease affecting about 1% of population.
One major problem in the treatment is finding the right the drug for the right patients. However,
pharmacogenetic results in psychiatry can seldom be replicated.
Methods: We selected three candidate genes associated with serotonergic neurotransmission for
the study: serotonin 2A (5-HT2A) receptor gene, tryptophan hydroxylase 1 (TPH1) gene, and G-
protein beta-3 subunit (GNB3) gene. We recruited 94 schizophrenia patients representing
extremes in treatment response to typical neuroleptics: 43 were good responders and 51 were
poor responders. The control group consisted of 392 healthy blood donors.
Results: We do, in part, replicate the association between 5-HT2A T102C polymorphism and
response to typical neuroleptics. In female patients, C/C genotype was significantly more common
in non-responders than in responders [OR = 6.04 (95% Cl 1.67–21.93), p = 0.005] or in the control
population [OR = 4.16 (95% CI 1.46–11.84), p = 0.005]. TPH1 A779C C/A genotype was inversely
associated with good treatment response when compared with non-responders [OR = 0.59 (95%
Cl 0.36–0.98), p = 0.030] or with the controls [OR = 0.44 (95% CI 0.23–0.86, p = 0.016], and GNB3
C825T C/T genotype showed a trend-like positive association among the male patients with a good
response compared with non-responders [OR = 3.48 (95% Cl 0.92–13.25), p = 0.061], and a
clearer association when compared with the controls [OR = 4.95 (95% CI 1.56–15.70), p = 0.004].
Conclusion: More findings on the consequences of functional polymorphisms for the role of
serotonin in the development of brain and serotonergic neurotransmission are needed before
more detailed hypotheses regarding susceptibility and outcome in schizophrenia can be formulated.
The present results may highlight some of the biological mechanisms in different courses of
schizophrenia between men and women.
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Schizophrenia is a devastating disease which affects about
one percent of people world-wide [1]. Recent studies sug-
gest that the interaction between brain dopaminergic and
serotonergic systems is of major significance in the neu-
ropathology and treatment of schizophrenia [2].
The pharmacogenetics of schizophrenia has focused on
studying dopamine and serotonin related genes [3]. Sev-
eral studies have found association between serotonergic
genes and response to clozapine [3]. In typical antipsy-
chotics, only few studies were related to dopamine recep-
tor genes and most results were negative for response
prediction [3,4]. Several lines of evidence indicate an
important role of serotonergic modulation in the mecha-
nism of action of typical neuroleptics. Although typical
neuroleptics act via dopamine-D2 receptor blockade, they
all (including haloperidol) affect both dopaminergic and
serotonergic receptors [5]. Altered serotonergic response
in brain have been reported in treatment-refractory
patients with schizophrenia [6]. Moreover, haloperidol
has been reported to increase 5-HT release in prefrontal
cortex [7]. Systemic administration of apomorphine, a
dopamine receptor agonist, has been found to both
decrease and increase striatal 5-HT release and increase 5-
HT release in the hippocampus [7]. Serotonin 5-HT2C
receptor affinity is also negatively correlated with the dose
of typical neuroleptics. Thus, increasing serotonin 5-
HT2C receptor antagonist affinity lowers the potency of
typical neuroleptics [8]. It is possible that actions of sero-
tonin receptors in addition to dopamine D2 receptors are
relevant to the actions of typical neuroleptics [9].
One study suggests that serotonin 2A (5-HT2A) receptor
gene polymorphism is associated with treatment response
to conventional antipsychotics [10]. In meta-analyses 5-
HT2A T102C polymorphism has been associated with the
risk of schizophrenia [11,12]. The 5-HT2A T102C C-allele
specific methylation has been associated with increased 5-
HT2A receptor expression in human temporal cortex [13],
and allele-specific methylation has been proposed as a
modulator in gene-environment interactions [14].
So far there have been no pharmacogenetic studies of
tryptophan hydroxylase 1 (TPH1) gene polymorphism in
schizophrenia. Genetic variation of TPH1 gene has been
associated with the risk of schizophrenia in two recently
published studies [15,16]. The TPH 779 A-allele has been
connected with lower CSF 5-HIAA concentrations in
healthy men [17]. TPH1 is mainly expressed in the pineal
gland, and it is responsible for peripheral serotonin
response, in contrast to TPH2, which is expressed in the
raphe nucleus and directly affects the serotonergic path-
ways of the brain [18]. The importance of TPH1 comes
through possible biological susceptibility through abnor-
mal serotonin levels during the development of brain
[19], or through abnormal response to stress [20], which
may further indicate mental disorders of several types,
and particularly schizophrenia.
The G-protein beta-3 subunit (GNB3) C825T polymor-
phism (T-allele) results in increased intracellular signal
transduction in G-protein coupled receptors [21]. TT gen-
otype or T allele carriers of C825T polymorphism have
been associated in three studies with treatment response
to serotonin selective reuptake inhibitors in the treatment
of depression [22-24]. GNB3 C825T polymorphism has
been associated with treatment response in various antip-
sychotic drugs [25] as well as clozapine induced weight
gain [26]. In addition, GNB3 polymorphism may predict
response of several other serotonergic treatments: triptans
[27], sibutramine [28], and electroconvulsive treatment
[29]. It is thus suggested that G-protein beta-3 subunit
may mediate the serotonergic effect at the second messen-
ger cascade level [30].
We hypothesized that these functional SNPs would alter
serotonergic neurotransmission and stress response in the
CNS, and might thus be suitable candidate genes for a
pharmacogenetic study with typical neuroleptics. The
hypothesis was tested in a study design including two
groups of schizophrenia patients with a well-documented
response, either good or poor to typical neuroleptics, and
resembling two different endophenotypes in their course
of the disorder and clinical response to treatment. As
TPH1 polymorphism is particularly interesting in relation
to stress response, which is in part regulated by estrogen
[31], we deemed it appropriate to analyse differences in
genotype distributions between the men and women in
our sample. The genotype distributions were compared
between the schizophrenia subgroups and the distribu-
tions of control group were also used as a reference.
Methods
Patients and controls
The patients were 94 unrelated Finnish patients with
schizophrenia. All patients met the criteria for schizophre-
nia of the Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV. Group 1 (responders) consisted of
patients with schizophrenia who had experienced suffi-
cient and sustained response to treatment with typical
antipsychotics. The patients in group 2 (non-responders)
had failed to respond to treatment with at least two differ-
ent typical antipsychotics. Because of poor response to
conventional neuroleptics, clozapine was initiated in all
patients in the non-responders' group. The control sample
consisted of 392 healthy blood donors (Table 1).
The study was performed in compliance with the code of
ethics of the World Medical Association (Declaration ofPage 2 of 6
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committee. The participants gave written informed con-
sent.
The responder group (group I, n = 43; 17 men, 26
women) consisted of patients who had experienced a suf-
ficient and long-lasting response to treatment with con-
ventional antipsychotics. Assessment of response was
based on information in hospital and mental health care
records and a personal interview with each patient. Before
initiation of antipsychotic treatment, the severity of schiz-
ophrenia symptoms had to be ≥ 4 according to the Clini-
cal Global Impression Scale (CGI). The patient records
were thoroughly reviewed from the time of the index hos-
pitalization or acute treatment in mental health care to
ensure that both the patient's psychotic symptoms had
disappeared and the level of functioning had returned to
a level corresponding to that prior the psychotic episode.
In addition, a clinical interview was conducted with each
patient during the time of the study to ascertain that the
good response had been sustained. The main conven-
tional antipsychotics used in the index treatment period
included chlorpromazine in fifteen, perphenazine, in
nine, chlorprothixene in six, zuclopentixole in five, thior-
idazine in four, haloperidol in three and flupentixole in
one of the cases.
The non-responders' group (group II, n = 51; 29 men, 22
women) comprised such patients on clozapine medica-
tion who had failed to respond to treatment with two dif-
ferent conventional antipsychotics on at least two
different occasions in a hospital setting. In each index
treatment period with conventional antipsychotics the
lowest accepted daily dose was 400 mg chlorpromazine
equivalent for a minimum of four weeks. Prior to the ini-
tiation of clozapine treatment the severity of symptoms of
schizophrenia had to be ≥ 4 on the CGI Scale, and at least
one of the following symptoms had to be present: concep-
tual disorganization, suspiciousness, hallucinatory behav-
ior, or unusual thought content. The main conventional
antipsychotics used in the two index treatment periods
included chlorpromazine in 23/8, perphenazine, in 5/2,
chlorprothixene in 6/9, zuclopentixole in 6/13, thiori-
dazine in 5/2, haloperidol in 4/13, levomepromazine in
2/2, flupentixole in 0/1 and sulpiride in 0/1 of the cases
(the numbers indicating first treatment period/second
treatment period).
DNA extraction and genotyping of the TPH1 A218C, 
A779C, GNB3 C825T and 5-HT2A T102C polymorphisms
Genomic DNA was extracted from peripheral blood leu-
kocytes using a commercially available kit and BioRobot
M48 Workstation according to manufacturer's instruc-
tions (Qiagen Inc., Hilden, Germany). DNA samples were
genotyped by employing the 5' nuclease assay and fluoro-
genic allele-specific TaqMan MGB probes [32] using the
ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). The nucleotide
sequences of primers and probes used in the PCR were
deduced from published sequences deposited in the Gen-
Bank and Celera databases and synthesized in conjuga-
tion with Applied Biosystems. Validated genotyping
assays were used for the TPH1 A779C (rs1799913), 5-
HT2A T102C (rs6313) and GNB3 C825T (rs6489738)
polymorphisms and custom assay for the TPH1 A218C
(rs1800532). PCR reaction containing genomic DNA, 1 ×
Universal PCR Master Mix, 900 nM of each primer and
200 nM of each probe was performed in 96-well plates
using the standard protocol in a total volume of 25 µl.
End-point fluorescence was measured and genotype call-
ing carried out by the allelic discrimination analysis mod-
ule after PCR resulting in clear identification of three
genotypes for all polymorphisms studied. All genotyping
was performed blind to the clinical formation.
Genotyping of 5-HT2A T102C polymorphism failed in
one patient (a non-responder) and in six control subjects.
Statistical analysis
We analysed the distributions of genotypes in both the
responders' and the non-responders' group in comparison
with the control group, and between both patient groups.
The differences of genotype distributions were calculated
using Pearson Chi-Square test and odds ratios between
groups were calculated from 2 × 2 contingency tables. Dif-
ferences in age, age at onset and antipsychotic dose
between genotype groups were calculated with ANOVA,
but no significant differences were found (p > 0.05).
In determining statistical power with the analyses of allele
frequencies between schizophrenia subgroups, we
assumed 80% of the patients in each group to be correctly
classified. With this assumption, the level of statistical
power with this analysis was ~0.9. For the analyses in
comparisons between patient subgroups and the control
group, the odds ratios needed for detecting differences in
genotype distributions were calculated with the power
level of 0.8. The distributions of different genotypes in the
control sample were used as references in these analyses.
Table 1: Characteristics of patient and control groups.
Sex M/F Age years Age at onset 
years
Responders (n = 43) 17/26 48.1 ± 11.4 32.2 ± 9.5
Non-responders (n = 51) 29/22 44.1 ± 10.5 27.5 ± 10.21
Controls 212/180 44.4 ± 11.1
1 p = 0.02 compared to responders (chi-square test)Page 3 of 6
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between groups in each genotype were 2.5–3.1 for the 5-
HT2A polymorphism, 2.5–2.6 for the TPH1 polymor-
phism, and 2.4–3.4 for the GNB3-825 polymorphism.
Data analysis was carried out using SPSS/Win (versions
12.0 and 14.0, SPSS Inc., Chicago, IL) and PS (version
2.1.31, (Dupont and Plummer 2004)) software. The level
of statistical significance was set at 0.05. The allele fre-
quencies of the genes studied were in Hardy-Weinberg
equilibrium.
Results
5-HT2A T102C polymorphism
In female patients, the C/C genotype was more common
in non-responders than in responders [OR = 6.04 (95% Cl
1.67–21.93), p = 0.005] or in the control population [OR
= 4.16 (95% CI 1.46–11.84), p = 0.005] (Table 2).
TPH1 A779C polymorphism
In the total sample, TPH1 C/A genotype was less common
in the responders' group compared with non-responders
[OR = 0.59 (95% Cl 0.36–0.98), p = 0.030] or with the
controls [OR = 0.44 (95% CI 0.23–0.86, p = 0.016] (Table
2).
GNB3 C825T polymorphism
In males, there was a trend-like association for C/T geno-
type to be more common in responders than in non-
responders [OR = 3.48 (95% Cl 0.92–13.25), p = 0.061].
In males, C/T genotype was more common in responders
than in controls [OR = 4.95 (95% CI 1.56–15.70), p =
0.004] (Table 2).
Discussion
The study models two endophenotypes of schizophrenia
in relation to the response with conventional neuroleptics
in comparison with the control subjects. The different
allele distributions in patient subgroups compared with
controls may indicate some part of the genetic susceptibil-
ity to schizophrenia, which has been linked to abnormal
stress response, and even more importantly different sub-
groups of the schizophrenic syndrome. The main problem
with the study methodology includes the small patient
sample, especially in comparisons between genders, but
on the other hand the selection criteria for both sub-
groups are restricted, resulting in marked differences in
the clinical picture between the patient groups, and less
variation in the course of the disease within the groups.
The selection criteria for these subgroups resulted in more
early-onset patients in the non-responder group, as could
be expected [33]. There was also a trend for more female
patients being selected in the responder group, but this
difference was not significant. Different distributions
between subgroups could in part be responsible for differ-
ent treatment effects, although the subgroups were
selected according to the response criteria. The compari-
sons between schizophrenia subgroups and control group
were performed in spite of small numbers of patients, and
acknowledging that the differences in allele distributions
deviated only slightly between the general schizophrenia
population and healthy controls, for example with the 5-
HT2A T102C polymorphism [11,12]. These comparisons
were necessary due to the strict selection criteria for schiz-
ophrenia subgroups, and the distributions of the control
group were used as references in these analyses.
5-HT2A T102C polymorphism
We report an association between 5-HT2A T102C poly-
morphism and response to typical neuroleptics, where C/
C genotype was associated with poor response in female
patients. Earlier, Joober et al. (1999) reported a similar
association in male patients but not in female patients.
The study design was very similar in both studies. How-
ever, an obvious reason for these different results may be
Table 2: Distribution of 5-HT2A, TPH1 and GNB3 gene polymorphisms in the study population.
5-HT2A TPH1 GNB3
CC CT TT CC CA AA CC CT TT
Patients responders (n = 43) 17 (39.5) 23 (53.5) 3 (7.0) 14 (32.6) 14 (32.6)2 15 (34.8) 18 (41.9) 20 (46.5) 5 (11.6)
females 9 (34.6) 14 (53.8) 3 (11.5) 8 (30.8) 9 (34.6) 9 (34.6) 14 (53.9) 7 (26.9) 5 (19.2)
males 8 (47.1) 9 (52.9) 0 (0.0) 6 (35.3) 5 (29.4) 6 (35.3) 4 (23.5) 13 (76.5)3 0 (0.0)
Patients non-responders (n = 51) 27 (54.0) 19 (38.0) 4 (8.0) 12 (23.5) 28 (54.9) 11 (21.6) 27 (53.0) 22 (43.1) 2 (3.9)
females 16 (76.2)1 4 (19.0) 1 (4.8) 3 (13.6) 13 (59.1) 6 (27.3) 13 (59.1) 8 (36.4) 1 (4.5)
males 11 (37.9) 15 (51.7) 3 (10.3) 9 (31.0) 15 (51.7) 5 (17.3) 14 (48.3) 14 (48.3) 1 (3.4)
Controls (n = 392) 166 (43.0) 176 (45.6) 44 (11.4) 106 (27.0) 205 (52.3) 81 (20.7) 218 (55.6) 144 (36.7) 30 (7.7)
females 77 (43.5) 81 (45.8) 19 (10.7) 42 (23.3) 90 (50.0) 48 (26.7) 107 (59.5) 60 (33.3) 13 (7.2)
males 89 (42.6) 95 (45.4) 25 (12.0) 64 (30.2) 115 (54.2) 33 (15.6) 111 (52.4) 84 (39.6) 17 (8.0)
Statistics: 1 p = 0.005, OR = 6.04 (95% Cl 1.67–21.93) compared to responders; p = 0.005, OR = 4.16 (95% CI 1.46–11.84) compared to controls
2 p = 0.030, OR = 0.59 (95% Cl 0.36–0.98) compared to non-responders; p = 0.016, OR = 0.44 (95% CI 0.23–0.86) compared to controls
3 p = 0.061, OR = 3.48 (95% Cl 0.92–13.25) compared to non-responders; p = 0.004, OR = 4.95 (95% CI 1.56–15.70) compared to controls
Abbreviations: 5-HT2A: serotonin 2A receptor gene; TPH1: tryptophan hydroxylase 1 gene, GNB3: G-protein beta-3 subunit gene.Page 4 of 6
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study by Joober et al. there were respectively 74.4% and
71.1% males in non-responders and responders. In the
present sample, there were 56.9% and 39.5% males in
these categories. One explanation for the gender differ-
ences detected may be that treatment-resistant women
with schizophrenia constitute a severely ill subgroup
within schizophrenia [34].
In meta-analysis, 5-HT2A T102C polymorphism has been
associated with a small schizophrenia increasing effect
[11,12]. Because of the small sample size in the schizo-
phrenia population, one would predict that such a small
contribution could not have been detected in the present
sample, and these analyses were therefore excluded from
this study.
The occurrence of 5-HT2A T102C C-allele has been found
to increase 5-HT2 receptor expression in human temporal
cortex [13]. There is evidence that the density of the 5-HT2
receptors is decreased in the prefrontal cortex of patients
with schizophrenia, but the results are still contradictory.
This phenomenon could reflect the heterogeneity of the
disease [35].
TPH1 A779C polymorphism
To our knowledge, this is the first report of an association
between TPH1 A779C polymorphism and response to
typical neuroleptics. We cannot present any conclusive
reason why the treatment response was inversely associ-
ated with a heterozygous genotype. However, heterosis is
a common feature which may occur in up to 50% of all
gene associations [36]. So far, the heterozygous C/A geno-
type has been reported to have a connection with higher
degrees of nicotine dependence, a feature strongly associ-
ated with schizophrenia [37]. The TPH1 A779C A-geno-
type has been associated with lowered serotonin
metabolite 5-HIAA levels in the CSF [17], and on the
other hand the functions of TPH1 are related to stress
response, which may be associated with susceptibility to
schizophrenia [20]. The role of TPH1 may also be impor-
tant during maturation of the serotonin neurons in the
brain [19].
GNB3 C825T polymorphism
Male heterozygous genotype carriers showed a better
response to typical neuroleptics. So far heterosis has been
reported by only one study, in which Korean male medi-
cal students were the more prone to seasonal variation the
more often they carried heterozygous genotype of GNB3
polymorphism [38]. It should be noted that several exam-
ples suggest that heterosis is gender specific [36]. How-
ever, no association between antipsychotic medication
response and the occurrence of T-allele, which has been
reported to have a GNB3 expression increasing effect [21]
was found in this study.
Conclusion
Serotonergic mechanisms may have a greater impact on
medication response of schizophrenia than has so far
been acknowledged. This approach needs more studies
including different endophenotypes of schizophrenia
regarding age at onset and medication response. These
subgroups are likely to have different susceptibility and
treatment response altering factors. The results of this
study may give rise to further hypotheses regarding the
role of gender in the course and outcome of schizophre-
nia.
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